Navigation Links
Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/3/2008

FAIRFIELD, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced that Dr. Roger G. Berlin, Chief Executive Officer of Arno, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at 2:00 PM EST in the Kennedy I room at the New York Palace Hotel in New York City. Dr. Berlin will provide a company overview and update on the status of Arno's current clinical development programs.

The presentation will be webcast live and can be accessed by visiting the Investor Relations second of Arno's website at http://www.arnothera.com. The webcast will be archived for 90 days.

About Arno Therapeutics

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead compound is AR-67, a novel third-generation camptothecin analogue entering Phase II clinical development in patients with various forms of cancer. Arno has completed enrollment in a single agent, ascending dose, Phase I clinical study of AR-67 in patients with advanced solid tumors. AR-67 has demonstrated high potency and significantly improved pharmacokinetic properties when compared with marketed second-generation products in its class. Arno is also developing two pre-clinical compounds. AR-12 is a potential first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway that is undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pathways also undergoing IND-enabling studies. Arno is actively pursuing additional compounds to expand its portfolio. For more information on Arno please visit http://www.arnothera.com.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Arno's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including those described under the caption "Risk Factors" in our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2008. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
2. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
3. United Therapeutics Reports Third Quarter 2008 Financial Results
4. Arete Therapeutics Bolsters Management Team
5. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
6. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
7. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
8. Nektar Therapeutics to Webcast R&D Day on November 12th
9. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
10. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
11. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)...  Phosphorus, a computational genomics and clinical genetic ... Phosphorus Scientific Advisory Board, an established group of ... company on the development of new products and ... http://phosphorus.com/about-us/ to learn more about the ... some of the top leaders in the field ...
(Date:2/28/2017)... , Feb. 28, 2017 WuXi AppTec, ... open-access capability and technology platform company, today announced ... Shanghai once again passed ... observations. The inspectors from FDA thoroughly ... focusing on scientific data integrity, operation infrastructure, equipment, ...
(Date:2/28/2017)... ... 2017 , ... ACEA Biosciences, a pioneer in cell analysis instrumentation and the ... (Feng) Luo as the new Vice President of Global Clinical Development. With more ... Dr. Luo will now team with Dr. Li Xu, Chief Medical Officer, and Dr. ...
(Date:2/28/2017)... and PHILADELPHIA , Feb. 28, 2017 ... held biopharmaceutical company focusing on debilitating diseases including rare ... announced that the company joins with the National Organization ... advocacy and support around the world in commemorating Rare ... unique challenges and needs of the millions of patients ...
Breaking Biology Technology:
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
Breaking Biology News(10 mins):